Apimeds - APUS Net earnings per share growth forecast for next year

Apimeds Pharmaceuticals (APUS) relies on unique patents for bee venom toxin purification to combat pain. This chart on GURU.Markets shows that the target net income per share growth reflects current dynamics, where 0.00 becomes the new value of the indicator. The company plans to capture the market through the expansion of biologics, with final FDA trial stages serving as the growth catalyst.

Apimeds (APUS): Net earnings per share growth forecast for next year from 05/10/2025 to 11/14/2026

Summary analytical data breakdowns for Apimeds Pharmaceuticals US (APUS)

- price and consensus price forecast:

Price Chart Apimeds Pharmaceuticals, Inc.|APUS - Fair Value Consensus

- issuer market value details:

Market Value Apimeds Pharmaceuticals|APUS - Total Enterprise Value

- company book value details:

Net Assets per Single Share Apimeds Pharmaceuticals|APUS - Company Book Value|Market Value to Book Value Ratio apimedsus.com|APUS - Company Assets

- issuer credit burden and liquidity indicators:

Total Debt to Capital Apimeds Pharmaceuticals|APUS - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Apimeds Pharmaceuticals, Inc.|APUS - Company Cumulative Debt|Debts to Book Capitalization Apimeds Pharmaceuticals|APUS - Company Long-Term Debts|Company Short-Term Debt Apimeds Pharmaceuticals|Quick Ratio apimedsus.com

- net income and valuation ratios data:

APUS - Net Financial Result|Expected Profit Apimeds Pharmaceuticals|APUS - Price to Earnings Ratio|Forward P/E Multiple Apimeds Pharmaceuticals, Inc.|APUS - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Apimeds Pharmaceuticals|APUS - Operating profit before amortization|Earnings per share for the last twelve months Apimeds Pharmaceuticals|APUS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months apimedsus.com|APUS - Earnings per share increase in current year|Net earnings per share growth forecast for next year Apimeds Pharmaceuticals

- company sales and revenue statistics:

APUS - Company Annual Revenue|Projected Sales Volume Apimeds Pharmaceuticals, Inc.|APUS - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Apimeds Pharmaceuticals

Fundamental company analysis:Apimeds Pharmaceuticals, APUS

Investors utilize this indicator to determine capitalization potential and business resilience through a consolidated EPS forecast. The development of innovative bee venom-based treatments for arthritis directly impacts this valuation of future earnings per share growth for Apimeds Pharmaceuticals (APUS). The positive trend in this metric confirms market confidence in the therapy's commercial success, shifting the asset into the category of high-yield speculative securities.

Main competitors